Mr. Ilan Sobel reports

BIOHARVEST SCIENCES ANNOUNCES NEW STRATEGIC HIRES FOR CDMO SERVICES BUSINESS UNIT

Bioharvest Sciences Inc. has appointed two senior hires in the areas of business development and science to spearhead key initiatives as part of the company's recently launched CDMO (contract development and manufacturing organization) services business unit.

"Our new CDMO services division is such a natural complement to the core competencies we've developed in our molecular research and product development teams," commented Bioharvest chief executive officer Ilan Sobel, adding, "but even with these powerful existing synergies, we needed to add leaders with specific skill sets in order to accelerate growth on both commercial and scientific levels to capitalize on major opportunities ahead."

Matt Zrebiec has been appointed as vice-president of business development -- with a focus on sourcing and closing new deals for the CDMO business unit. Mr. Zrebiec leverages 23 years of experience in the branded specialty, biotech, generics and CDMO pharmaceutical sector. He previously served in leadership roles at Teva, Wyeth Vaccines, Par Endo, Lupin, Hikma and Piramal Pharma. He pulls on a deep expertise in business development and licensing, corporate development, mergers and acquisitions, analytics modleling, portfolio strategy, CDMO lead gen, application programming interface sales, and life cycle management. Mr. Zrebiec has managed large teams and delivered complex deals, creating significant value for his prior organizations.

Prof. Itay Mayrose has been appointed as a senior artificial intelligence (AI) scientist, spearheading development initiatives as part of the CDMO business unit. Prof. Mayrose is a globally recognized expert in plant computational genomics, renowned for his multidisciplinary approach that merges computer science with biological research. His research encompasses multiple fields, spanning genomics, molecular biology, ecology and phylogenetics. Prof. Mayrose pioneered the use of artificial intelligence into genome editing and evolutionary studies, leading to groundbreaking discoveries. Research led by his team was published in the most prestigious scientific journals, including Nature, Science, Nature Plants, Nature Ecology & Evolution, and Nature Communications.

Dr. Zaki Rakib, chairman of Bioharvest and president of the CDMO services business unit, added: "I am pleased to welcome Matt Zrebiec and Prof. Itay Mayrose to the Bioharvest Sciences team, where they will play a key role in driving forward the momentum of our recently launched CDMO services business unit. Our CDMO division lies at the intersection of biology and mathematics, and with Dr. Itay's guidance, we can apply AI algorithms for machine learning, helping to accelerate the molecule development process. On the commercial side, we are gaining momentum and have several exciting CDMO partnership opportunities in our deal pipeline. I look forward to working with the team to close new deals, further expanding our reach into the pharma, cosmetics and nutrition industries."

Bioharvest CDMO corporate update webinar -- Wednesday, March 13, 2024, 2:30 p.m. EST

CEO Mr. Sobel and chairman Dr. Rakib will host the call at 2:30 p.m. Eastern Time on Wednesday, March 13, 2024, with a formal presentation to discuss the launch of the CDMO business unit, provide a corporate update, and conclude with a question-and-answer session. To participate, all interested media and investors are invited to preregister.

About Bioharvest Sciences Inc.

Bioharvest Sciences is a leader in botanical synthesis, leveraging its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. Bioharvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.

We seek Safe Harbor.